Is there still a role for bilateral orchidectomy in androgen-deprivation therapy for metastatic prostate cancer?

Mohamed Adel Atta, Ahmed Elabbady, Wael Sameh, Mohamed Sharafeldeen and Mohamed Elsaqa

Department of Urology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt

**ABSTRACT**

**Objective:** To compare bilateral orchidectomy, as the classical ‘gold standard’ androgen-deprivation therapy (ADT), and ADT using a luteinising hormone-releasing hormone (LHRH) antagonist (degarelix) for the treatment of metastatic prostate cancer regarding their short-term biochemical efficacy, testosterone castrate level, tolerability, and effect on health-related quality of life (HRQoL).

**Patients and methods:** A total of 60 patients with newly diagnosed metastatic prostate cancer were managed by either bilateral orchidectomy or degarelix injection as ADT. Both groups were compared according to their prostate-specific antigen (PSA) nadir and testosterone level at the 6-month follow-up. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) after 12 months.

**Results:** Bilateral orchidectomy and degarelix showed comparable results for PSA reduction, but there was a statistically significantly lower castrate level of testosterone in the bilateral orchidectomy group. Using the EROTC QLQC-30, bilateral orchidectomy was associated with better HRQoL, better global health status, and better functional status.

**Conclusion:** Bilateral orchidectomy resulted in lower castrate levels of testosterone, which may be associated with better disease control, together with better HRQoL and general health status compared to LHRH antagonist (degarelix). These results indicate that we should consider revisiting bilateral orchidectomy as a valuable and effective treatment option for ADT.

**Abbreviations:** ADT: androgen-deprivation therapy; EORTC (QLQ-C30): European Organisation for Research and Treatment of Cancer (Quality of Life Questionnaire-Core 30); HRQoL: health-related quality of life

**Introduction**

Metastatic prostate cancer has a profound response to androgen deprivation. Since 1941, when Huggins and Hodges proved the favourable effects of androgen deprivation by surgical castration or oestrogen administration on the progression of metastatic prostate cancer, androgen-deprivation therapy (ADT) has been the mainstay for the management of advanced prostate cancer to date [1]. Bilateral orchidectomy is the traditional ‘gold standard’ for androgen deprivation. It is a simple surgical procedure and can even be done under local anaesthesia [2]. Patients with symptomatic metastasis show significant improvement within 24–48 h after bilateral orchidectomy [3]. In patients accepting bilateral orchidectomy, it is considered the most cost-effective form of androgen ablation [4].

For a long time, LHRH agonists have been used as an alternative method of androgen deprivation. LHRH agonists result in suppression of LH from the anterior pituitary gland and consequently, results in an inhibition of testosterone [5,6]. However, LHRH agonists initially activate the receptors, resulting in a surge in LH and testosterone, as well as a delayed reduction in PSA levels for 2–3 weeks before androgen deprivation is achieved [7,8]. The surge can delay the therapeutic benefit and may exacerbate the clinical status by provoking or exacerbating symptoms such as urinary retention, bone pain, and paraplegia due to spinal-cord compression by spinal metastases, this is referred to as the flare-up phenomenon or hormonal surge [7,8].

Novel LHRH antagonists do not induce a testosterone surge but work by immediately suppressing the release of gonadotrophins and testosterone. Degarelix is a novel LHRH antagonist with weak histamine-releasing properties and a more rapid and profound testosterone suppression compared to trials of other LHRH antagonists [9–11].

Although ADT is effective in the management of prostate cancer, it has various side-effects that may impact on health-related quality of life (HRQoL), especially with long-term ADT. Adverse effects of ADT include hot flushes, sexual dysfunction, fatigue, accelerated osteoporosis, increased body fat, and impaired cognitive functions [12,13]. As prostate cancer is generally a disease of elderly men, many patients present...
with significant comorbidities that have a detrimental impact on life expectancy. Consequently, the potential benefits of ADT must be weighed against its potential hazards and impact on HRQoL [14,15].

In the present study, we compared bilateral orchidectomy and LHRH antagonist (namely degarelix) as ADT for the treatment of newly diagnosed metastatic prostate cancer regarding efficacy, tolerability, and HRQoL.

Patients and methods

This prospective study included patients with newly diagnosed metastatic prostate cancer who presented to Alexandria University hospitals between October 2015 and October 2017. All patients had positive bone scans for metastasis. Patients were counselled about both methods of androgen deprivation and they were assigned to one of the two groups according to their preferences:

- Group I: Patients treated by bilateral orchidectomy.
- Group II: Patients treated by subcutaneous degarelix (Firmaxon™; Ferring Pharmaceuticals, Saint-Prex, Switzerland) injection. Loading dose of 240 mg and maintenance dose of 80 mg monthly injections were given.

All patients were subjected to the following:

- Baseline detailed assessment.
- Follow-up hormonal assessment of serum PSA and serum testosterone at 6 months after the start of hormonal therapy.
- Assessment of HRQoL using the validated Arabic version [16,17] of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) at the 12-month follow-up [18].

The QLQ-C30 includes 30 questions that assess both physical and psychological aspects of the patient’s health. It assesses the ability to perform usual physical and social activities, as well as general physical complaints such as fatigue, nausea, vomiting, constipation, and dyspnoea. From the questionnaire, three main items can be evaluated; the functional scale, symptom scale, and global health scale. Each scale is measured by a score ranging from zero to 100.

For statistical analysis, the chi-square, Fisher’s exact or Monte Carlo correction tests were used to determine a significant relationship between nominal/categorical variables, whilst the Student’s t-test or Mann–Whitney test were used for ordinal/continuous variables. The P value for statistical significance was set at P < 0.05.

| Variable                              | Group I (bilateral orchidectomy) | Group II (degarelix) | P      |
|---------------------------------------|----------------------------------|----------------------|--------|
| Number of patients                    | 33                               | 27                   |        |
| Age, years, mean (SD)                 | 67.73 (7.24)                     | 67.80 (7.73)         | 0.973* |
| Gleason Groups, n (%)                 | 6 (18.2)                         | 2 (7.4)              | 0.027**|
| Group 1                               | 6 (18.2)                         | 2 (7.4)              |        |
| Group 2                               | 3 (9.1)                          | 2 (7.4)              |        |
| Group 3                               | 6 (18.2)                         | 15 (55.6)            |        |
| Group 4                               | 10 (30.3)                        | 2 (7.4)              |        |
| Group 5                               | 8 (24.2)                         | 6 (22.2)             |        |
| Serum PSA level (ng/mL), n (%)        | 4 (12.1)                         | 4 (14.8)             | 0.912**|
| <20                                   | 5 (15.2)                         | 3 (11.1)             |        |
| 20–50                                 | 24 (72.7)                        | 20 (74.1)            |        |
| Bone pain                             | 33 (100)                         | 25 (92.5)            | 0.492***|
| Obstructive uropathy                  | 21 (63.6)                        | 15 (55.6)            | 0.791  |
|                                      | 6 (18.2)                         | 0                   | 0.024  |

*Chi-square test, **Monte Carlo correlation, ***Fisher’s exact correlation.

Results

The study included 60 consecutive patients; 33 in Group I and 27 in Group II. All the patients in the degarelix arm continued the treatment to the 12-month follow-up. The mean (SD) age was 67 (7) years in both groups. The mean (SD) initial PSA level was 240.8 (43) ng/mL in Group I and 306 (63) ng/mL in Group II. There was no significant statistical difference between the groups for age and initial presenting serum PSA level. Using the new International Society of Urological Pathology (ISUP) Gleason groups [19], there was a tendency towards more aggressive Gleason groups in Group I, with 18 patients in Group I with Gleason Group 4 or 5, whereas in Group II there were only eight patients with high grades (Table 1).

Most of the patients presented with LUTS or bone pain. None of the degarelix-group patients (Group II) presented with obstructive uropathy, whereas six of the 33 patients (18.2%) in the bilateral orchidectomy group (Group I) presented with obstructive uropathy and were managed by nephrostomy tube insertion. The patients who presented with obstructive uropathy in Group I were aged >60 years (range 60–72 years) and Gleason Group 4 or 5 (Table 1).

Serum PSA and serum testosterone levels

The presenting and follow-up PSA and percentage of PSA reduction between presentation and post-treatment follow-up were compared in both groups as shown in Table 2. After 6 months of treatment, in Group I the follow-up PSA level varied between 0.1 and 34 ng/mL, with a mean (SD) PSA level of 9.37 (10.04) ng/mL; while in Group II the follow-up PSA level varied between 0.02 and 34.5 ng/mL, with a mean (SD) PSA level of 7.55 (11.79) ng/mL. The initial and follow-up PSA levels were not significantly different in both groups.
The mean (SD) percentage PSA reduction in Group I was 91.9 (12.3)% compared to the presenting levels and in Group II was 93.1 (10.2)%. There was no statistically significant difference between the groups. The follow-up serum testosterone level in Group I varied from 0.002 to 0.7 ng/mL, with a mean (SD) testosterone level of 0.178 (0.197) ng/mL; while in Group II the testosterone level varied from 0.09 to 0.49 ng/mL, with a mean (SD) testosterone level of 0.297 (0.125) ng/mL. There was a statistically significantly lower serum testosterone level in Group I, as shown in Table 2.

**HRQoL assessment with the QLQ-C30**

The Arabic version of the EORTC QLQ-C30 questionnaire completed by the patients at the 12-month follow-up was analysed and the scoring system was applied to evaluate the functional scale, symptom scale and global health scale. The mean (SD) global health status was 81.94 (10.51)% in Group I and 74.17 (11.23)% in Group II (P < 0.008). The mean (SD) functional scale score was 85.26 (7.66)% in Group I and 78.15 (6.23)% in Group II (P < 0.001). The mean (SD) symptom scale score was 14.19 (6.31)% in Group I and 20.60 (6.26)% in Group II (P < 0.001). Thus, Group I had a significantly better global health status and functional scale score, and lower symptom scale score than Group II (Figure 1).

**Discussion**

In our present study, bilateral orchidectomy and degarelix had comparable results for reducing the PSA level at 6 months of follow-up; however, the castrate level of testosterone was significantly lower with bilateral orchidectomy. Although the castrate level of testosterone is considered by the regulatory authorities, the threshold that has been used in all clinical trials is still 50 ng/dL (1.7 nmol/L). Oefelein et al. [3] reported that the median testosterone value after bilateral orchidectomy was 15 ng/dL and they considered a castrate level as <20 ng/dL (1 nmol/L). Other studies have highlighted the possibility that lower testosterone levels may be associated with improved outcomes, including increased time to the development of castrate-resistant disease and overall survival [20,21]. In a series of 162 men with metastatic prostate cancer treated with LHRH agonist, Perachino et al. [20] reported that the prognosis was found to be related to 6-month testosterone levels, with longer survival with lower testosterone levels. Similarly, Morote et al. [21] strongly suggested that patients experiencing a breakthrough testosterone during LHRH agonist therapy have a reduced progression-free survival rate compared with those who did not experience testosterone breakthroughs.

Our present study is the first to compare degarelix to bilateral orchidectomy. Multiple studies have evaluated the efficacy and tolerability of degarelix in comparison to LHRH agonists. Klotz et al. [22] analysed the pooled data of five randomised comparative clinical trials of degarelix vs LHRH agonists. The pooled data showed that PSA progression-free and overall survival were improved in the degarelix group. Also, degarelix was associated with fewer joint-related signs and symptoms, musculoskeletal events, and urinary tract events.

Due to the concern about the adverse effects of hormonal therapy, HRQoL and global health status in patients receiving hormonal therapy for prostate cancer has been a focus of many studies. Two recent

---

**Table 2.** Comparison between the two studied groups according to serum PSA and testosterone castrate levels.

| Variable                                      | Group I (bilateral orchidectomy) | Group II (degarelix) | P*  |
|-----------------------------------------------|----------------------------------|----------------------|-----|
| Initial PSA level, ng/mL, mean (SD; range)    | 240.89 (433.19; 1–1935)          | 305.47 (632.81; 9–2161) | 0.767 |
| Follow-up PSA level (at 6 months), ng/mL, mean (SD; range) | 9.37 (10.04; 0.1–34.0) | 7.55 (11.79; 0.02–34.5) | 0.108 |
| % PSA reduction, mean (SD)                   | 91.92 (12.31)                    | 93.14 (10.22)        | 0.676 |
| Serum testosterone castrate level, ng/mL, mean (SD; range) | 0.178 (0.197; 0.02–0.7) | 0.297 (0.125; 0.09–0.49) | 0.001 |

*Mann–Whitney test.

Figure 1. Comparison between HRQoL scales in both groups.
studies have compared the incidence of adverse events between surgical castration and LHRH agonists [23,24]. The studies showed that bilateral orchidectomy was associated with a reduced risk of adverse events, especially skeletal-related events, peripheral arterial disease, cardiac-related complications, and diabetes mellitus.

With the use of the EORTC QLQ-C30, the general HRQoL was assessed in both of the present groups. The results of our present study have shown that bilateral orchidectomy was associated with better HRQoL and global health status with a lesser symptoms score than patients who used degarelix. The reason for a better HRQoL in the case of bilateral orchidectomy is uncertain, but this may be attributed to the lower testosterone castration level, which could reflect better disease control. Although concerns about psychological insult with surgical castration is always raised, patients that choose bilateral orchidectomy may experience less worry and concern about cancer control than patients receiving monthly degarelix injections.

The limitations of the present study include: the small number of patients, the non-randomised nature of the study, the lack of a pre-treatment HRQoL assessment, and the short-term follow-up. Further studies with long-term follow-up and a larger number of cases may be needed.

Conclusion

Although degarelix has shown considerable effectiveness and safety for the management of prostate cancer, bilateral orchidectomy was associated with lower testosterone levels, which may reflect better disease control, and better HRQoL and general health status. These results indicate that we should consider revisiting bilateral orchidectomy as a valuable and effective treatment option for ADT.

Disclosure statement

No potential conflict of interest was reported by the authors.

ORCID

Mohamed Elsaqa  
http://orcid.org/0000-0003-3341-3648

References

[1] Huggins C, Stevens RE Jr, Hodges CV. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209–223.
[2] Desmond AD, Arnold AJ, Hastie KJ. Subcapsular orchidectomy under local anaesthesia. Technique, results and implications. Br J Urol. 1988;61:143–145.
[3] Oeeflein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56:1021–1024.
[4] Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer: cost-effectiveness of hormonal therapy options. European Association of Urology Guidelines; 2015. [cited 2019 November]. Available from: https://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2015-En.pdf
[5] Heber D, Dodson R, Stokopf C, et al. Pituitary desensitisation and the regulation of pituitary gonadotropin-releasing hormone (GnRH) receptors following chronic administration of a superactive GnRH analog and testosterone. Life Sci. 1982;30:2301–2308.
[6] McKillop C. Interview with Professor Ulf Tunn: IHRHa: what’s new? Interview by Christine McKillop. Eur Urol. 2007;51:275–277.
[7] Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol. 2001;165:1585–1589.
[8] Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80.
[9] Broqua P, Riviere PJ, Conn PM, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther. 2002;301:95–102.
[10] Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotrophin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer. Eur Urol. 2008;54:805–815.
[11] Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomised, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–1538.
[12] Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin North Am. 2006;20:909–923.
[13] Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261.
[14] Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171:2285–2290.
[15] Newschaffer CJ, Otani K, McDonald MK, et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000;92:613–621.
[16] Awad MA, Denic S, El Taji H. Validation of the European organization for research and treatment of cancer quality of life questionnaires for Arabic-speaking populations. Ann NY Acad Sci. 2008;1138:146–154.
[17] Huijer HA, Sagherian K, Tamim H. Validation of the Arabic version of the EORTC QLQ-C30 quality of life questionnaire among cancer patients in Lebanon. Qual Life Res. 2013;22:1473–1481.
[18] Fayers P, Aaronson NK, Bjordal K, et al. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: EORTC Quality of Life Group; 2001; p. 86.
[19] Epstein JT, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: A validated alternative to the Gleason score. Eur Urol. 2016;69:428–435.
[20] Perachino M, Cavalli V, Monferrato C. Testosterone (T) level correlates with survival in pts with advanced prostate cancer (APC): the lower is really the better. J Urol. 2008;179:179–180.

[21] Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol. 2007;178:1290–1295.

[22] Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66:1101–1108.

[23] Sun M, Choueiri T, Hamnvik O, et al. Comparison of gonadotropin-releasing hormone agonists and orchiectomy. JAMA Oncol. 2016;4:500–507.

[24] Van Asseldonk B, Black P, Elterman DS. Chemical vs surgical ADT in metastatic prostate cancer: a comparison of side effects. Commentary on comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen deprivation therapy. Urology. 2016;93:3–4.